Julie Borland
Overview
Explore the profile of Julie Borland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song I, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski M, et al.
J Acquir Immune Defic Syndr
. 2016 Mar;
72(4):400-7.
PMID: 26974526
Background: Dolutegravir is an integrase strand transfer inhibitor (INSTI) licensed for use in HIV-1 infection and is an inhibitor of organic cation transporter 2 (OCT2). This study assessed the effect...
2.
Song I, Weller S, Patel J, Borland J, Wynne B, Choukour M, et al.
Eur J Clin Pharmacol
. 2016 Feb;
72(6):665-70.
PMID: 26898568
Purpose: Dolutegravir (DTG) is primarily metabolized by UGT1A1 with CYP3A as a minor route. Carbamazepine (CBZ) is a potent inducer of these enzymes; thus, the effect of oral extended-release CBZ...
3.
Song I, Borland J, Savina P, Chen S, Patel P, Wajima T, et al.
Clin Pharmacol Drug Dev
. 2015 Jun;
2(4):342-348.
PMID: 26097786
This study evaluated dolutegravir pharmacokinetics (PK) in subjects with moderate hepatic impairment compared to matched, healthy controls. In this open-label, parallel-group study, eight adult subjects with moderate hepatic impairment (Child-Pugh...
4.
Song I, Borland J, Chen S, Wajima T, Peppercorn A, Piscitelli S
Ann Pharmacother
. 2015 Apr;
49(7):784-9.
PMID: 25862012
Background: Dolutegravir (DTG; Tivicay; ViiV Healthcare, Research Triangle Park, NC) is an HIV-1-unboosted integrase inhibitor with no cytochrome P450 or uridine 5'diphosphate-glucuronosyltransferase inhibition or induction. As DTG is administered to...
5.
Song I, Borland J, Arya N, Wynne B, Piscitelli S
J Clin Pharmacol
. 2014 Dec;
55(5):490-6.
PMID: 25449994
All commercially available integrase inhibitors are 2-metal binders and may be affected by co-administration with metal cations. The purpose of this study was to evaluate the effect of calcium and...
6.
Zong J, Borland J, Jerva F, Wynne B, Choukour M, Song I
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19584.
PMID: 25394090
Introduction: Dolutegravir (DTG) is an HIV integrase strand transfer inhibitor approved for use in combination with other antiretrovirals for the treatment of HIV-infection in adults and adolescents. Metformin is a...
7.
Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli S
Antimicrob Agents Chemother
. 2014 Aug;
58(11):6696-700.
PMID: 25155604
Dolutegravir (DTG) is an HIV integrase inhibitor (INI) with demonstrated activity in INI-naive and INI-resistant patients. The objective of this open-label, 2-period, single-sequence study was to evaluate the effect of...
8.
Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, et al.
Eur J Clin Pharmacol
. 2014 Aug;
70(10):1173-9.
PMID: 25146692
Purpose: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in...
9.
Johnson M, Borland J, Chen S, Savina P, Wynne B, Piscitelli S
Br J Clin Pharmacol
. 2014 May;
78(5):1043-9.
PMID: 24838177
Aims: The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with...
10.
Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli S
J Acquir Immune Defic Syndr
. 2014 May;
66(4):393-8.
PMID: 24798770
Background: The integrase inhibitor dolutegravir and nucleoside analogues abacavir and lamivudine are once-daily treatment options for HIV. This study (NCT01622790) evaluated, first, the bioequivalence (BE) of a fixed-dose combination (FDC)...